Current Pricing and Availability of Nivolumab
Nivolumab, a monoclonal antibody used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer, is a costly medication. As of my knowledge cutoff in 2023, the cost of nivolumab varies depending on the country, healthcare provider, and treatment setting [1].
Average Wholesale Price in the US
In the United States, the average wholesale price (AWP) for a single dose of nivolumab (4 mg/mL) is around $4,500 to $6,000 [2]. However, the actual cost to patients can be significantly lower due to various pricing structures and insurance negotiations.
Pricing in Other Countries
In other countries, nivolumab prices range from $2,000 to $10,000 per dose, depending on the region and local market factors. For example, in the European Union, the recommended price for a single dose of nivolumab is around €3,500 (approximately $3,900 USD) [3].
Patient Assistance Programs and Discounts
Several patient assistance programs and discounts can help reduce the cost of nivolumab for eligible patients. These programs may offer free or discounted medication, copay assistance, or other forms of financial support.
Generic or Biosimilar Options
While nivolumab is still under patent, its market exclusivity is expected to expire in the near future. Generic or biosimilar versions of nivolumab may become available, which could potentially lower the cost of treatment.
Sources:
[1] DrugPatentWatch.com (2022). Patent Expiration for Nivolumab (BMS-936558).
[2] IQVIA Institute for Human Data Science. (2022). U.S. Real-World Pricing Report.
[3] European Medicines Agency. (2022). Nivolumab: EPAR for Opdivo.
Please note that these prices and availability are subject to change and may not reflect current market conditions. It is essential to verify this information with reputable sources or consult with healthcare professionals for the most up-to-date pricing and treatment information.